PDCD1 and non-small cell lung carcinoma: Another phase 3 study (NCT04921358)26 is evaluating sitravatinib plus tislelizumab (a PD-1 inhibitor) in patients with locally advanced/metastatic NSCLC who experienced disease progression after CPI and chemotherapy.